4.6 Article

Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Editorial Material Oncology

Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables

James R. Anderson et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Article Oncology

Progression-free survival is a surrogate for survival in advanced colorectal cancer

Marc Buyse et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

Article Oncology

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

Marc C. Chamberlain et al.

JOURNAL OF NEURO-ONCOLOGY (2007)

Article Medicine, General & Internal

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

R Stupp et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Article Oncology

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

SM Chang et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)